<DOC>
	<DOCNO>NCT03039257</DOCNO>
	<brief_summary>The primary objective study establish single dose vitamin A supplementation feasible safe pediatric young adult bone marrow transplant recipient day +30 ( ± 7 day ) hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Vitamin A Replacement Patients Undergoing HSCT Its Role MBI-LCBI Rates</brief_title>
	<detailed_description>The investigator ' preliminary data suggest low level vitamin A directly impact risk mucosal barrier injury laboratory-confirmed bloodstream infection ( MBI-LCBI ) , likely via decrease gut permeability , hypothesize supplemental vitamin A time HSCT reduce risk MBI-LCBI gastrointestinal graft versus host disease ( GI GVHD ) . A 3x3 dose escalation/de-escalation study design use determine safety dose require maintain vitamin A level upper quartile normal range age day +30 ( ± 7 day ) single dose vitamin A supplementation prior hematopoietic stem cell transplantation .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<criteria>Any patient undergoing HSCT . Vitamin A hypersensitivity allergy . Age le 1 year time transplant . Baseline preHSCT vitamin A level high upper quartile normal range age . Enteral feed medication intolerance . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematopoietic stem cell transplant</keyword>
	<keyword>vitamin</keyword>
</DOC>